129 / 1631
PORT
Trial design
•
All registered patients will receive 4 infusions of pembrolizumab given at 3 weekly
intervals at a dose of 200mg.
•
At 12 weeks, patients will start radiotherapy : 12Gy in 3 fractions.
•
Patients who progress on pembrolizumab before week 12 will start radiotherapy as
soon as possible after progression.
•
Following completion of radiotherapy patients will continue pembrolizumab until
disease progression or unacceptable toxicity.
Week
0 3 6 9 12 15 18 21 24
Pembrolizumab
200mg i.v.
x x x x x x x x x
Radiotherapy 12 Gy in 3
fractions
x